THE ONLY 1% FORMULATION of loteprednol etabonate (LE).
THE ONLY MUCOPENETRATING technology for ophthalmic use.
THE ONLY corticosteroid FDA approved for BID TREATMENT of
post-operative inflammation and pain following ocular surgery.
Drug Delivery Technology enhances penetration through the mucus barrier using 2 proprietary attributes1:
AMPPLIFY® delivered more LE to target ocular tissues vs Lotemax® Suspension5
*Data from an in vivo preclinical study in 36 male rabbits, aged 6 months. Animals were randomized to receive either loteprednol etabonate 1% with AMPPLIFY® Drug Delivery Technology or Lotemax ®Suspension. Concentrations of study drugs in the aqueous humor and cornea were assayed at 5 minutes, 15 minutes, 30 minutes, 1.0, 3.0, and 6.0 hours postdosing. Clinical significance of this preclinical data has not been established.
Traditional suspension eye drops adhere to mucins and can be rapidly cleared through blinking
Drug particles formulated with AMPPLIFY® are designed to enhance penetration through the mucus barrier and deliver increased concentrations to the target ocular tissues
(vs vehicle) with no concurrent NSAID use (P<0.01)*
ZERO Inflammation in 50% of patients
by Day 15
Complete resolution of inflammation (anterior chamber cell count=0), INVELTYS vs vehicle:
(93/386)(51/385)
ZERO Pain in nearly 70% of patients
by Day 15
Complete resolution of pain (grade=0), INVELTYS vs vehicle:
(164/386)(96/385)
LOW Incidence of significant intraocular
pressure (IOP) elevations5
Incidence of significant IOP elevations (≥10 mm Hg increase from baseline with a total measurement of ≥21 mm Hg), INVELTYS vs vehicle:
(2/386)(0/385) If INVELTYSis used for
10 days or longer,
IOP should be
monitored.
*Clinical efficacy and safety were evaluated in 2 multicentered, randomized, double-masked, placebo-controlled trials in which patients with an anterior cell grade ≥2 (ie, a cell count of 6 or higher using a slit-lamp biomicroscope) after cataract surgery were assigned to INVELTYS (n=386; Study 1, n=125; Study 2, n=261) or placebo (vehicle) (n=385; Study 1, n=126; Study 2, n=259) following surgery. One to 2 drops of INVELTYS or vehicle were self-administered twice a day for 14 days beginning the day after surgery. Complete resolution of inflammation (a cell count of 0) and complete resolution of pain (a patient-reported pain grade of 0 [rated via the Subject-Rated Ocular Pain Assessment, 0=none to 5=severe]) were assessed 4, 8, and 15 days postsurgery. Consolidated clinical trial results provided above.
- Shake bottle for 1 to 2 seconds before using
- Instill 1 to 2 drops into the affected eye twice daily, beginning the day after surgery and continuing throughout the first 2 weeks of the post-operative period
- Contact lenses should be removed prior to instillation of INVELTYS and may be reinserted after 15 minutes following administration
BID STRONG with...a Commitment to patient Access
For eligible patients whose prescriptions for INVELTYS are not covered by either commercial or government insurance, use of the co-pay card may reduce co-payment responsibility to
AS LITTLE AS $60
Restrictions and conditions apply.
Thoughts from Ophthalmic Experts
How do mucins in the tear film affect eye drop delivery?
Why is BID dosing important for your patients?
How would you describe the intraocular pressure profile of INVELTYS?
What is AMPPLIFY® Drug Delivery Technology?
Why would you prescribe INVELTYS for the management of pain and inflammation following ocular surgery?
What should I tell my patients to do if the pharmacy tries to switch their prescription?